BridgeBio Pharma (BBIO) Invested Capital (2017 - 2026)

BridgeBio Pharma has disclosed Invested Capital across 10 years of filings, most recently posting $384.9 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $384.9 million, up 123.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $384.9 million (up 123.49% YoY), and the FY2025 annual result was -$1.5 billion, down 50.88% from the prior year.
• Invested Capital came in at $384.9 million for Q1 2026 at BridgeBio Pharma, up from -$1.5 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $384.9 million in Q1 2026 to a low of -$1.8 billion in Q2 2025.
• The 5-year median for Invested Capital is -$1.2 billion (2023), against an average of -$1.1 billion.
• Across the five-year window, Invested Capital tumbled 13126.74% in 2022 and soared 123.49% in 2026, its largest moves.
• BridgeBio Pharma's Invested Capital stood at -$1.2 billion in 2022, then declined by 8.02% to -$1.3 billion in 2023, then rose by 24.02% to -$1.0 billion in 2024, then slumped by 50.88% to -$1.5 billion in 2025, then soared by 125.0% to $384.9 million in 2026.
• The last three Invested Capital figures came in at $384.9 million (Q1 2026), -$1.5 billion (Q4 2025), and $74.3 million (Q3 2025), per Business Quant data.